Skip to main content
Premium Trial:

Request an Annual Quote

Illumina, Covaris Ink Co-marketing Pact

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Covaris announced today that it has signed a co-marketing deal with Illumina related to sequencing sample preparation.

Under the agreement, the firms will co-market Covaris' DNA shearing technologies with Illumina's next-generation sequencing product lines including the HiSeq, HiScanSQ, and Genome Analyzer.

According to Woburn, Mass.-based Covaris, its technology "enables higher recoveries for nucleic acid extraction, tissue homogenization, chromatin shearing, protein digestion, and cell lysis." It also is isothermal and non-contact, which ensures molecular stability.

Financial and other terms of the alliance were not disclosed.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.